Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehman, Jonathan M., aMassion, Pierre P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677662/
https://www.ncbi.nlm.nih.gov/pubmed/31413814
http://dx.doi.org/10.18632/oncotarget.27107
_version_ 1783440929006288896
author Lehman, Jonathan M.
aMassion, Pierre P.
author_facet Lehman, Jonathan M.
aMassion, Pierre P.
author_sort Lehman, Jonathan M.
collection PubMed
description Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.
format Online
Article
Text
id pubmed-6677662
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-66776622019-08-14 Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives Lehman, Jonathan M. aMassion, Pierre P. Oncotarget Research Paper Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC. Impact Journals LLC 2019-07-30 /pmc/articles/PMC6677662/ /pubmed/31413814 http://dx.doi.org/10.18632/oncotarget.27107 Text en Copyright: © 2019 Lehman et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Lehman, Jonathan M.
aMassion, Pierre P.
Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title_full Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title_fullStr Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title_full_unstemmed Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title_short Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
title_sort somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677662/
https://www.ncbi.nlm.nih.gov/pubmed/31413814
http://dx.doi.org/10.18632/oncotarget.27107
work_keys_str_mv AT lehmanjonathanm somatostatinreceptor2targetinginsmallcelllungcarcinomaperspectives
AT amassionpierrep somatostatinreceptor2targetinginsmallcelllungcarcinomaperspectives

Ejemplares similares